We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Biomarker May Predict Sudden Heart Failure

By LabMedica International staff writers
Posted on 13 Sep 2012
A blood test can predict who would benefit from Implantable Cardioverter Defibrillators (ICD), which are surgically implanted in heart failure patients to prevent sudden death,

The straightforward laboratory test can tell with high accuracy which patients will or will not require an ICD for the next 12 months that would prevent arrhythmia and its subsequent cardiac arrest. More...


Physicians at the Chicago College of Medicine (IL, USA) carried out a clinical trial on 180 adults participants of whom 135 of them had heart failure, and 45 were healthy individuals as the control group. They excluded people with inflammatory conditions, infections, and congenital heart disease. The blood test, called PulsePredic, detects alterations in the messenger ribonucleic acid (mRNA) for the sodium channel, voltage-gated, type V, alpha subunit (SCN5A) gene, which previous studies have shown to be closely linked with sudden death. The increase in the altered mRNA was found to be a good predictor of which patients were most likely to have a sudden death episode requiring defibrillation.

The scientists measured the SCN5A gene in white blood cells and heart muscle cells. By analyzing the alterations in the mRNA, they could predict who would have a sudden death episode where defibrillation would be required. The patients with heart failure who had arrhythmias that would cause sudden death were found to have considerably higher levels of these genetic mutations, compared to those with normal heartbeats. By measuring variant levels in the blood, they were able to predict surprisingly accurately who had arrhythmic risk, suggesting that it is possible to have a blood test for sudden death risk and the need for an ICD.

Certain proteins, called voltage-gated sodium channels, are responsible for generating the main current for the electrical signals in the heart. The SCN5A gene encodes for these proteins. Arrhythmias occur when there are rises or falls in the sodium current. Samuel C. Dudley, MD, PhD, chief cardiologist at the University of Illinois (Chicago, IL, USA), explained, “The test predicts whether you will have sudden death from heart failure and whether you will need a defibrillator in the next year." Professor Dudley is the CEO of ROS Technologies, Inc., the university’s spinoff company that will develop the blood test. The study was presented at the European Society of Cardiology Congress 2012, held in Munich (Germany).

Related Links:

Chicago College of Medicine
University of Illinois




New
Gold Member
Hybrid Pipette
SWITCH
Portable Electronic Pipette
Mini 96
Human Estradiol Assay
Human Estradiol CLIA Kit
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.